Last updated: May 29, 2026

Application No. 18/099,319

ORAL CAPSULE AND PREPARATION METHOD THEREFOR

Final Rejection

Filed

Jan 20, 2023

Priority

Jun 10, 2019 — CN PCT/CN2019/090543 +2 more

Examiner

KUCHARCZK, JED A

Art Unit

1623

Tech Center

1600 — Biotechnology & Organic Chemistry

Assignee

BEIGENE, LTD.

OA Round

5 (Final)

Interview Optional

— +15.6% interview lift. Interview already conducted in this application's prosecution history. This examiner has a 80% grant rate with +15.6% interview lift. Since an interview has already been tried, recommend written response with narrowed claims based on precedent claim evolution patterns.

Based on 91 resolved cases, 2023–2026

Examiner Intelligence

KUCHARCZK, JED A View full profile →

Grants 80% — above average

Career Allowance Rate

73 granted / 91 resolved

+20.2% vs TC avg

Strong +16% interview lift

Without

With

+15.6%

Interview Lift

resolved cases with interview

Typical timeline

2y 9m

Avg Prosecution

24 currently pending

Career history

117

Total Applications

across all art units

Statute-Specific Performance

§101

1.0%

-39.0% vs TC avg

§103

45.9%

+5.9% vs TC avg

§102

19.0%

-21.0% vs TC avg

§112

9.8%

-30.2% vs TC avg

Black line = Tech Center average estimate • Based on career data from 91 resolved cases

Prosecution Timeline

Show 11 earlier events

Apr 30, 2024

Examiner Interview (Telephonic)

Jun 14, 2024

Request for Continued Examination

Jun 20, 2024

Response after Non-Final Action

Oct 07, 2024

Response Filed

Feb 05, 2025

Non-Final Rejection mailed

Jul 03, 2025

Response Filed

Oct 16, 2025

Final Rejection mailed

Apr 18, 2026

Response after Non-Final Action

Precedent Cases

Applications granted by this same examiner with similar technology

16/965,252

Patent 12629349

Recognition ability improving agent

5y 9m to grant Granted May 19, 2026

17/796,449

Patent 12630529

GCN2 MODULATOR COMPOUNDS

3y 9m to grant Granted May 19, 2026

19/242,489

Patent 12630533

HETEROCYCLIC COMPOUNDS USEFUL AS KCNT1 INHIBITORS

11m to grant Granted May 19, 2026

17/893,081

Patent 12617804

CONJUGATION-FUSED BIPOLAR REDOX-ACTIVE MOLECULE, PREPARATION METHOD, AND APPLICATION THEREOF

3y 8m to grant Granted May 05, 2026

17/286,716

Patent 12600710

BETA-CATENIN AND B-CELL LYMPHOMA 9 (BCL9) INHIBITORS

4y 12m to grant Granted Apr 14, 2026

Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.

Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

6-7

Expected OA Rounds

80%

Grant Probability

96%

With Interview (+15.6%)

2y 9m (~0m remaining)

Median Time to Grant

High

PTA Risk

Based on 91 resolved cases by this examiner. Grant probability derived from career allowance rate.